Dominik M.
- Country
- Germany
- Department
- Klinik und Poliklinik für Neurologie
Research Overview
- Phase III Double-Blind, Randomized, Placebo-Controlled Trial of Intravenous Tenecteplase for Visual Recovery in Acute Non-Arteritic Central Retinal Artery Occlusion
- A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke
- Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusion
Data & Insights
Has run more than one trial at 116 of 379 partner sites.
Specializations
Cerebrovascular Disorders
The investigator specializes in treating acute ischemic stroke and transient ischemic attack, with particular emphasis on innovative therapeutic approaches for improving patient outcomes in emergency stroke care.
- Large vessel occlusion treatment
- Post-stroke reperfusion therapy
- Emergency stroke intervention
Advanced expertise in mechanical thrombectomy and post-procedural care for patients with incomplete reperfusion.
Neuro-Ophthalmology
Focuses on treating central retinal artery occlusion (CRAO), implementing early intervention protocols for vision preservation and recovery in acute cases.
- Visual acuity restoration
- Retinal reperfusion therapy
- Non-arteritic CRAO management
Specialized interest in developing treatment protocols for acute vision loss due to retinal arterial occlusion.
Therapeutic Innovation
Evaluates novel therapeutic agents including redasemtide, tenecteplase, and milvexian for acute cerebrovascular conditions.
- Neuroprotective strategies
- Intra-arterial therapeutics
- Secondary stroke prevention
Expertise in conducting clinical trials for emerging stroke treatments and preventive therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.